Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02515240 · ClinicalTrials.gov registry record · Early Phase 1
Immune Response to Pneumococcal Vaccination in HIV Infected Individuals
A Early Phase 1 study, sponsored by University of Toledo Health Science Campus.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 124
- Enrollment target
NCT02515240 is a Early Phase 1 study that has completed, run by University of Toledo Health Science Campus. The registered enrollment target is 124 participants.
The verdict
NCT02515240, a Early Phase 1 study, has completed, sponsored by University of Toledo Health Science Campus.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 124 participants
- Enrollment target
Study Summary
The purpose of the study. To characterize the immune response to the pneumococcal vaccine in HIV positive individuals and to dissect the most appropriate timing and frequency of vaccination.
Interventions
- BIOLOGICAL PPV23
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2010-07 |
| Est. Completion | 2015-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02515240
The ClinicalTrials.gov registry entry for NCT02515240 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Toledo Health Science Campus, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PPV23 is the first listed.
NCT02515240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02515240 about?
NCT02515240 is a clinical study titled "Immune Response to Pneumococcal Vaccination in HIV Infected Individuals". The purpose of the study. To characterize the immune response to the pneumococcal vaccine in HIV positive individuals and to dissect the most appropriate timing and frequency of vaccination.
What is the current status of trial NCT02515240?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 124 participants. The study started on 2010-07. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02515240?
The interventions under investigation include: PPV23 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02515240?
This trial is sponsored by University of Toledo Health Science Campus, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.